HEALTH ALERT! If you have any of the following, please call our office before coming in for your appointment: Fever AND cough; Fever OR cough and recent travel (domestic or international to any destination); Recent international travel to areas impacted by the Coronavirus (2019-nCoV) within the last 14 days; OR close contact with someone who has traveled outside the US or been exposed to the Coronavirus. Read more

USOR 19094 STAR Ph3 Infigratinib UC w/FGFR3 Alt PROOF302 QBGJ398-302

USOR 19094: QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations. (PROOF302)

Disease Types: Bladder,  Urothelial,&nbs

Available at: Arlington Heights

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}